2. Search Result
Search Result
Results for "

IL-17A inhibitor

" in MedChemExpress (MCE) Product Catalog:

28

Inhibitors & Agonists

3

Inhibitory Antibodies

2

Natural
Products

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-139206
    LY3509754
    2 Publications Verification

    IL-17A inhibitor 1

    		 Interleukin Related Inflammation/Immunology
    LY3509754 (IL-17A inhibitor 1) is a IL-17A inhibitor, with IC50 values of <9.45 nM and 9.3 nM in alphalisa assay and HT-29 cells .
    LY3509754
  • HY-145429
    IL-17A modulator-2

    		Interleukin Related Neurological Disease Inflammation/Immunology Cancer
    IL-17A modulator-2 is a IL-17A modulator, extracted from patent WO2021239743+A1, example 27. IL-17A modulator-2 inhibits the biological action of IL-17A with a pIC50 of 8.3. IL-17A modulator-2 can be used for the research of diseases or disorders associated with modulation of IL-17A activity including diseases with an immune component or autoimmune pathol, cancer and neurodegenerative disorders .
    IL-17A modulator-2
  • HY-145430
    IL-17A modulator-1

    		Interleukin Related Neurological Disease Inflammation/Immunology Cancer
    IL-17A modulator-1 is a IL-17A modulator, extracted from patent WO2021239743+A1, example 9. IL-17A modulator-1 inhibits the biological action of IL-17A with a pIC50 of 8.2. IL-17A modulator-1 can be used for the research of diseases or disorders associated with modulation of IL-17A activity including diseases with an immune component or autoimmune pathol, cancer and neurodegenerative disorders .
    IL-17A modulator-1
  • HY-P990222
    Anti-Mouse IL-17A Antibody (17F3)

    		Interleukin Related Others
    Anti-Mouse IL-17A Antibody (17F3) is a mouse-derived IgG1, κ type antibody inhibitor, targeting to mouse IL-17A.
    Anti-Mouse IL-17A Antibody (17F3)
  • HY-P99335
    Vunakizumab

    Anti-Human IL17A Recombinant Antibody

    		 Interleukin Related Inflammation/Immunology
    Vunakizumab (Anti-Human IL17A Recombinant Antibody) is a recombinant human IgGκ monoclonal antibody that targets IL-17A and inhibits its interaction with the IL-17 receptor. Vunakizumab can be used to study autoimmune diseases such as psoriatic arthritis, ankylosing spondylitis, multiple sclerosis and inflammatory arthritis .
    Vunakizumab
  • HY-139686
    IL-17A inhibitor 2

    		Interleukin Related Inflammation/Immunology
    IL-17A inhibitor 2 is an IL-17A inhibitor for researching psoriasis, rheumatoid arthritis, and multiple sclerosis.
    IL-17A inhibitor 2
  • HY-169306
    IL-17A inhibitor 4

    		Interleukin Related Inflammation/Immunology
    IL-17A inhibitor 4 (Example 449) is a potent IL-17A inhibitor. IL-17A inhibitor 4 inhibits HTRF and NHK cells viability with IC50s of 0.028 and 0.0047 μM, respectively .
    IL-17A inhibitor 4
  • HY-148272
    IL-17A modulator-3

    		Interleukin Related Inflammation/Immunology Cancer
    IL-17A modulator-3 (compound 253) is a IL-17A modulator. IL-17A modulator-3 inhibits IL-17A/A with an IC50 value ＜10 μM. IL-17A modulator-3 can be used for the research of inflammation, cancer and autoimmune disease .
    IL-17A modulator-3
  • HY-158159
    IL17A-IN-1

    		Interleukin Related Inflammation/Immunology Cancer
    IL17A-IN-1 (compound 72) is an orally active Interleukin 17A inhibitor. IL17A-IN-1 can be used in the study of inflammatory and autoimmune diseases (plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis, etc.), as well as cancer .
    IL17A-IN-1
  • HY-153780
    Navepdekinra

    		Interleukin Related Inflammation/Immunology
    Navepdekinra (Example 210) is a potent interleukin-17A (IL-17A) inhibitor with anti-inflammatory activity .
    Navepdekinra
  • HY-N12481
    Cephalandole B

    		Others Inflammation/Immunology
    Cephalandole B is an indigo alkaloid that has the activity of inhibiting IL-17A gene expression. Cephalandole B significantly inhibited the activity of IL-17A luciferase reporter gene in Jukat cells, and this inhibitory effect was dose-dependent. Cephalandole B may have important application prospects in inflammation-related research .
    Cephalandole B
  • HY-P99515
    Xeligekimab

    GR 1501

    		 Interleukin Related Inflammation/Immunology
    Xeligekimab (GR 1501) is an anti-human interleukin 17A (IL-17A) humanized monoclonal antibody. Xeligekimab inhibits the pro-inflammatory cascade .
    Xeligekimab
  • HY-153276
    Androgen receptor-IN-5

    		Androgen Receptor Cancer
    Androgen receptor-IN-5 is an androgen receptor inhibitor with potent anticancer effects. Androgen receptor-IN-5 also inhibits the production of IL-17A, IL- 17F and INF-γ (WO2023281097A1,Example 1/1) .
    Androgen receptor-IN-5
  • HY-164826
    Acetyl zingerone

    		Interleukin Related Inflammation/Immunology
    Acetyl zingerone is a new multifunctional skincare ingredient that protects melanocytes from ongoing DNA damage. Acetyl zingerone inhibits matrix metalloproteinases and suppresses the expression of the IL-17A target genes, having anti-inflammatory and antioxidant activities .
    Acetyl zingerone
  • HY-170611
    IL-17-IN-3

    		Interleukin Related Inflammation/Immunology
    IL-17-IN-3 (compound 11) is an IL-17A inhibitor with an IC50 value of 35 nM. IL-17-IN-3 exhibits no adverse effects in a rat tolerability study after a four-day administration of up to 300 mg/kg/day .
    IL-17-IN-3
  • HY-152851
    Izumerogant

    IMU-935

    		 ROR Others Cancer
    Izumerogant (IMU-935) is an inverse agonist of retinoid-related orphan receptor-gamma (RORγ). Izumerogant (compound 123) also potently inhibits IL-17A, IL-17F and IFN-γ activity with IC50s <50 nM .
    Izumerogant
  • HY-139780
    JNJ-61803534

    		ROR Inflammation/Immunology
    JNJ-61803534 is a potent and orally active RORγt inverse agonist with an IC50 of 9.6  nM. JNJ-61803534 has anti-inflammatory activity. JNJ-61803534 inhibits IL-17A production in human CD4+ T cells under Th17 differentiation conditions .
    JNJ-61803534
  • HY-168084
    IL-17-IN-1

    		Interleukin Related Inflammation/Immunology
    IL-17-IN-1 (26) is an orally active IL-17 inhibitor, with IC50 values of 0.013 μM and 0.004 μM for IL-17A and IL-6 release, respectively. IL-17-IN-1 (26) effectively reduces knee swelling in a rat arthritis model .
    IL-17-IN-1
  • HY-169007
    STAT3-IN-34

    		STAT Inflammation/Immunology
    STAT3-IN-34 (Compound 15E) is an inhibitor for STAT3, and inhibits the nuclear translocation and transcriptional regulator activity of STAT3. STAT3-IN-34 inhibits the proliferation of cell HaCaT with IC50 of 0.008 μM. STAT3-IN-34 inhibits IL-17A expression and ameliorates Imiquimod (HY-B0180)-induced psoriasis in mice .
    STAT3-IN-34
  • HY-162490
    TF-S14

    		ROR Inflammation/Immunology
    TF-S14 is a reverse agonist of RORγt. TF-S14 reduces Th17 cell-associated cytokine production, including IL-17A, IL-21, and IL-22 by binding to and inhibiting RORγt activity. TF-S14 can be used in the study of autoimmune diseases and rejection in allotransplantation .
    TF-S14
  • HY-107390A
    AX-024 hydrochloride
    1 Publications Verification

    		 TNF Receptor Interleukin Related IFNAR Inflammation/Immunology Cancer
    AX-024 hydrochloride is an orally available, first-in-class inhibitor of the TCR-Nck interaction that selectively inhibits TCR-triggered T cell activation with an IC50 ~1 nM. AX-024 hydrochloride modulates cell signaling by targeting SH3 domains. AX-024 hydrochloride has low-acute toxicity and high potency and selectivity, and strongly inhibit the production of IL-6, TNF-α, IFN-γ, IL-10 and IL-17A.
    AX-024 hydrochloride
  • HY-107390
    AX-024
    1 Publications Verification

    		 TNF Receptor Interleukin Related IFNAR Inflammation/Immunology Cancer
    AX-024 is an orally available, first-in-class inhibitor of the TCR-Nck interaction that selectively inhibits TCR-triggered T cell activation with an IC50 ~1 nM. AX-024 modulates cell signaling by targeting SH3 domains. AX-024 has low-acute toxicity and high potency and selectivity, and strongly inhibit the production of IL-6, TNF-α, IFN-γ, IL-10 and IL-17A.
    AX-024
  • HY-15826
    SGC-CBP30
    Maximum Cited Publications
    13 Publications Verification

    		 Epigenetic Reader Domain Histone Acetyltransferase Inflammation/Immunology Cancer
    SGC-CBP30 is a potent and highly selective CBP/p300 bromodomain (Kds of 21 nM and 32 nM for CBP and p300, respectively) inhibitor, displaying 40-fold selectivity over the first bromodomain of BRD4 [BRD4(1)] bound. SGC-CBP30 strongly reduces secretion of IL-17A in Th17 cells and has anti-inflammatory effects .
    SGC-CBP30
  • HY-N11768
    4-Methoxylonchocarpin

    		NF-κB Interleukin Related Toll-like Receptor (TLR) Inflammation/Immunology
    4-Methoxylonchocarpin is an orally active anti-inflammatory agent. 4-methoxylonchocarpin inhibits the binding of LPS to Toll-like Receptor (TLR) TLR4 to inhibit NF-κB activation and TNF Receptor and IL-6 expression. 4-Methoxylonchocarpin also inhibits the phosphorylation of TGF-beta activated kinase 1 and TNBS-induced expression of IL-1β, IL-17A, and TNF. 4-methoxylonchocarpin can improve 2,4, 6-trinitrobenzene sulfonic acid (TNBS)-induced colitis mouse model .
    4-Methoxylonchocarpin
  • HY-103637
    Vimirogant

    VTP-43742

    		 ROR Inflammation/Immunology
    Vimirogant (VTP-43742) is a potent, selective, and orally active RORγt inhibitor (Ki=3.5 nM; IC50=17 nM). Vimirogant exhibits >1000-fold selectivity versus the RORα and RORβ isotypes. Vimirogant inhibits Th17 differentiation and IL-17A secretion from mouse splenocytes (IC50=57 nM) without affecting Th1, Th2, or Treg cell differentiation. Vimirogant has the potential for autoimmune disorders research .
    Vimirogant
  • HY-103637A
    Vimirogant hydrochloride
    1 Publications Verification

    VTP-43742 hydrochloride

    		 ROR Inflammation/Immunology
    Vimirogant (VTP-43742) hydrochloride is a potent, selective, and orally active RORγt inhibitor (Ki=3.5 nM; IC50=17 nM). Vimirogant hydrochloride exhibits >1000-fold selectivity versus the RORα and RORβ isotypes. Vimirogant hydrochloride inhibits Th17 differentiation and IL-17A secretion from mouse splenocytes (IC50=57 nM) without affecting Th1, Th2, or Treg cell differentiation. Vimirogant hydrochloride has the potential for autoimmune disorders research .
    Vimirogant hydrochloride
  • HY-155243
    12R-LOX-IN-1

    		DNA/RNA Synthesis Inflammation/Immunology
    12R-LOX-IN-1 (Compound 4a) is a 12R-LOX inhibitor (IC50: 28.25 μM). 12R-LOX-IN-1 inhibits the hyper-proliferative state and colony forming potential of Imiquimod (HY-B0180)-induced psoriatic keratinocytes. 12R-LOX-IN-1 inhibits reactive oxygen species, Ki67, IL-17A, TNF-α and IL-6 production. 12R-LOX-IN-1 can be used for antipsoriatic research .
    12R-LOX-IN-1
  • HY-155244
    12R-LOX-IN-2

    		Lipoxygenase DNA/RNA Synthesis Inflammation/Immunology
    12R-LOX-IN-2 (compound 7b) is an inhibitor of 12R-lipoxygenase (12R-LOX). 12R-LOX-IN-2 inhibits imiquimod (IMQ)-induced hyperproliferation of psoriatic keratinocytes and suppresses colony formation. 12R-LOX-IN-2 also reduced the protein level of Ki67 and the mRNA expression of IL-17A in IMQ-induced cells. 12R-LOX-IN-2 can be used in research into psoriasis and other skin-related inflammatory diseases .
    12R-LOX-IN-2

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: